$222 Million is the total value of OUP Management Co., LLC's 16 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ionQ, Inc. | $69,256,000 | – | 4,147,081 | +100.0% | 31.22% | – | |
| CYT | New | Cyteir Therapeutics, Inc. | $28,136,000 | – | 2,474,572 | +100.0% | 12.68% | – |
| CNTA | New | Centessa Pharmaceuticals plcsponsored ads | $26,370,000 | – | 2,341,891 | +100.0% | 11.89% | – |
| PMVP | New | PMV Pharmaceuticals, Inc. | $22,851,000 | – | 989,232 | +100.0% | 10.30% | – |
| New | DICE Therapeutics Inc. | $13,584,000 | – | 536,693 | +100.0% | 6.12% | – | |
| LABP | New | Landos Biopharma, Inc. | $8,772,000 | – | 1,827,478 | +100.0% | 3.95% | – |
| New | eFFECTOR Therapeutics, Inc. | $8,493,000 | – | 1,025,697 | +100.0% | 3.83% | – | |
| DTIL | New | Precision BioSciences, Inc. | $8,317,000 | – | 1,123,913 | +100.0% | 3.75% | – |
| New | Evolv Technologies Holdings, Inc. | $8,121,000 | – | 1,820,866 | +100.0% | 3.66% | – | |
| AVTE | New | Aerovate Therapeutics Inc. | $7,118,000 | – | 603,762 | +100.0% | 3.21% | – |
| GRPH | New | Graphite Bio | $5,050,000 | – | 406,308 | +100.0% | 2.28% | – |
| New | Sera Prognostics, Inc. | $4,406,000 | – | 641,361 | +100.0% | 1.99% | – | |
| VOR | New | Vor Biopharma Inc. | $4,354,000 | – | 374,714 | +100.0% | 1.96% | – |
| SPRO | New | Spero Therapeutics, Inc. | $3,988,000 | – | 249,070 | +100.0% | 1.80% | – |
| SELB | New | Selecta Biosciences, Inc. | $2,812,000 | – | 862,543 | +100.0% | 1.27% | – |
| FIXX | New | Homology Medicines, Inc. | $233,000 | – | 64,000 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
| Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
| PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
| Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
| Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
| Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
| Graphite Bio | 8 | Q3 2023 | 2.3% |
| eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
| Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
| Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-24 |
| 13F-HR | 2023-02-02 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-19 |
| 13F-HR | 2022-05-04 |
| 13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.